The therapeutic landscape of metastatic hormone-sensitive prostate cancer (mHSPC) has expanded significantly with triplet regimens, raising questions about their real-world applicability. This study evaluates the efficacy and safety of darolutamide- and abiraterone-based triplets using real-world data from the ARON-3 study.
A retrospective analysis was conducted on 247 mHSPC patients treated with DARO+DOCE+ADT or ABI+DOCE+ADT across 37 institutions in 14 countries. Key outcomes included progression-free survival (PFS), overall survival (OS), PSA kinetics, and safety. A propensity score was estimated based on key clinical variables and included as a covariate in Cox regression models to adjust for baseline imbalances between treatment groups.
Data from 247 patients receiving triplet therapy were analyzed. The median OS for the entire cohort was not reached (NR). The median PFS was 24.8 months (95% CI: 18.7-33.6), with NR for DARO+DOCE+ADT and 21.5 months (95% CI: 13.1-25.2) for ABI+DOCE+ADT (P=0.007). In patients with visceral metastases, DARO+DOCE+ADT demonstrated superior outcomes, achieving higher OS rates at 6 months (97% vs. 83%, P=0.002) and 12 months (92% vs. 74%, P<0.001) compared to ABI+DOCE+ADT. The safety profiles of both regimens were comparable, although grade 3-4 fatigue was more frequently observed in the ABI+DOCE+ADT group. After adjusting for baseline imbalances through propensity score inclusion in multivariate models, the differences in OS (P=0.103) and PFS (P=0.135) between treatment groups did not reach statistical significance, although a numerical trend favoring DARO+DOCE+ADT was observed.
Both regimens demonstrate efficacy, with DARO+DOCE+ADT offering superior outcomes in high-volume disease, especially visceral metastases. Nonetheless, the limited sample size and potential biases highlight the need for further follow-up and biomarker-driven studies in larger cohorts to refine treatment strategies.
Minerva urology and nephrology. 2026 Jun 23 [Epub ahead of print]
Pasquale Rescigno, Tarek Taha, Maria J Fita, Diana Matthews, Kazutoshi Fujita, Cristian Lolli, Fabrizio DI Costanzo, Alvaro Juárez, Yüksel Ürün, Sati C Yazgan, Haoran Li, Gaetano Facchini, María N Quiroga, Enrico Sammarco, Martin Bögemann, Daniele Santini, Jalal Baranseh, Giandomenico Roviello, Ray M Kopp, Ondřej Fiala, Thomas Büttner, Francesco Carrozza, Jawaher Ansari, Deniz Tural, Vincenza Conteduca, Javier Molina-Cerrillo, Teresa Alonso-Gordoa, Maria T Bourlon, Georgia A Palacios, Federico Paolieri, Anca Zgura, Roberta DI Rocco, Leonardo G Lacerenza, Marc R Matrana, Angelo Martignetti, Francesco Massari, Andrey Soares, Fernando S Monteiro, Diogo A Bastos, Luke Gaughan, Mike Wenzel, Philipp Mandel, Giuseppe L Banna, Matteo Santoni
Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK - ., The Royal Marsden NHS Foundation Trust, London, UK., Medical Oncology, Fundación Instituto Valenciano de Oncología, Valencia, Spain., Velindre Cancer Center, Cardiff, UK., Department of Urology, Kindai University Faculty of Medicine, Kindai, Japan., Department of Medical Oncology, Dino Amadori IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola, Forlì-Cesena, Italy., Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK., Department of Urology, Jerez University Hospital, Jerez, Spain., Department of Medical Oncology, Ankara University Medical Faculty, Ankara, Türkiye., Division of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center, Westwood, KS, USA., Oncology Unit, S. Maria Delle Grazie Hospital, Pozzuoli, Naples, Italy., Ángel H. Roffo Oncologic Institute, Buenos Aires, Argentina., Unit of Medical Oncology, Livorno Hospital, Azienda Toscana Nord Ovest, Livorno, Italy., Department of Urology, University Hospital of Münster, Münster, Germany., Unit of Oncology, Department of Sciences and Medico-Surigical Sciences, Umberto I Polyclinic, Rome, Italy., Department of Oncology, Rambam Health Care Campus, Haifa, Israel., Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy., Department of Clinical Oncology, Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia., Department of Oncology and Radiotherapeutics, Faculty of Medicine, University Hospital of Pilsen, Charles University, Pilsen, Czech Republic., Department of Urology, University Hospital Bonn (UKB), Bonn, Germany., Unit of Oncology, Department of Oncology and Haematology, Santa Maria delle Croci Hospital, AUSL Romagna, Ravenna, Italy., Department of Medical Oncology, Tawam Hospital, Al Ain, United Arab Emirates., Department of Medical Oncology, Koc University Medical Faculty, Istanbul, Türkiye., Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, Foggia, Italy., Department of Medical Oncology, Ramón y Cajal University Hospital, Madrid, Spain., Salvador Zubirán National Institute of Medical and Nutritional Sciences, Mexico City, Mexico., Department of Medical Oncology, Sant Pau Institute of Biomedical Investigation, Santa Creu I Sant Pau Hospital, Barcelona, Spain., Department of Oncology, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy., Department of Medical Oncology, Prof. Dr. Al. Trestioreanu Oncological Institute, Bucharest, Romania., Ospedale Misericordia Grosseto, Asl Toscana Sud Est, Grosseto, Italy., Department of Internal Medicine, Hematology/Oncology, Ochsner Medical Center, New Orleans, LA, USA., Department of Oncology, USL Sud Est Toscana - Area Senese, Poggibonsi, Siena, Italy., Department of Medical Oncology, IRCCS University Hospital of Bologna, Bologna, Italy., Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil., Department of Medical Oncology, Sírio-Libanês Hospital, São Paulo, Brazil., Department of Urology, University Hospital of Frankfurt, Goethe University, Frankfurt am Main, Germany., Portsmouth Hospitals University NHS Trust, Portsmouth, UK., Medical Oncology Unit, Macerata Hospital, Macerata, Italy.